- Data from DELIVER and ACHIEVE Clinicals Trial to be Presented -
Read the original post:
Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference
Related Post
- Benitec Biopharma Announces Acceptance of Late- Breaking Oral Abstract for the BB-301 Phase 1b/2a Clinical Study at the Muscular Dystrophy Association... - February 15th, 2025
- ORYZON Announces Journal Publication of Final Phase IIa REIMAGINE Results with Vafidemstat in Psychiatry and Clinical Neurosciences - February 15th, 2025
- Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update - February 15th, 2025
- Nasdaq confirms Evaxion is fully compliant, withdraws delisting determination - February 15th, 2025
- Artelo Biosciences Announces New Data on ART12.11 Tablets Showing Improved Pharmacokinetics to Epidiolex® - February 15th, 2025
- IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML - February 15th, 2025
- Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update - February 15th, 2025
- Longeveron to Present at the Emerging Growth Virtual Conference on February 19, 2025 - February 15th, 2025
- Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) - February 15th, 2025
- Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency - February 15th, 2025
- Tevogen Bio CEO Addresses Short Selling and Its Potential Impact on the Nation’s Health and Prosperity - February 15th, 2025
- Entero Therapeutics Appoints Richard Paolone as CEO - February 15th, 2025
- NurExone Biologic Continues Expansion of U.S. Presence and Awareness with Prestigious Conference Presentation - February 15th, 2025
- Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 15th, 2025
- Natural Alternatives International, Inc. Announces 2025 Q2 and YTD Results - February 15th, 2025
- Edesa Biotech Reports Fiscal 1st Quarter 2025 Results - February 15th, 2025
- Bavarian Nordic Receives U.S. FDA Approval of Chikungunya Vaccine for Persons Aged 12 and Older - February 15th, 2025
- Tevogen Bio CEO Reinforces Commitment to Retention of Equity Capital and Long-Term Vision - February 15th, 2025
- PacBio Grants Equity Incentive Award to New Employee - February 15th, 2025
- Rakovina Therapeutics Announces Additional Synthesized Compounds in its AI-Driven Cancer Drug Discovery Program - February 7th, 2025
- Intelligent Bio Solutions expects to achieve 32.6% Gross Profit Expansion and Increased Profitability on Higher-Margin Sales - February 7th, 2025
- Wave Life Sciences Announces Initiation of Phase 1 INLIGHT Clinical Trial of WVE-007 in Obesity - February 7th, 2025
- North Texas Took Center Stage at Advanced Therapies Week 2025, Highlighting Innovation and Collaboration in Life Sciences - February 7th, 2025
- BioAdaptives Welcomes UFC Senior Executive Reed Harris to Its Board of Advisors - February 7th, 2025
- GUERBET : 2024 revenue. - February 7th, 2025
- Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa - February 7th, 2025
- Shareholding declaration Valneva SE - January 2025 - February 7th, 2025
- Ipsen - January 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital - February 7th, 2025
- CARBIOS is pleased that the European Commission has authorised the ‘Circular Economy’ State aid scheme - February 7th, 2025
- 60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - February 7th, 2025
- Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - February 7th, 2025
- Senseonics Completes CE Mark Submission for Eversense 365, World’s Longest-lasting Continuous Glucose Monitor - February 7th, 2025
- Codexis Appoints Arthur Levin, PhD, to Strategic Advisory Board - February 7th, 2025
- Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative... - February 7th, 2025
- GENFIT Outlines Anticipated New Clinical Trial Initiations, Development Milestones and Data Readouts in 2025 - February 7th, 2025
- PharmAla Signs Advisory Agreement with Mr. Matthew Azrieli - February 7th, 2025
- Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025 - February 7th, 2025
- Press Release: Execution of a share buyback agreement for up to €2 billion - February 7th, 2025
- Novo Nordisk A/S: Once-weekly Mim8 is well-tolerated and efficacious in children living with haemophilia A with and without inhibitors - February 7th, 2025
- Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer - November 27th, 2024
- Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference - November 27th, 2024
- Tectonic Therapeutic To Present on December 3rd, 2024 at the Piper Sandler Healthcare Conference - November 27th, 2024
- Fate Therapeutics to Present at Upcoming December Investor Conferences - November 27th, 2024
- Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx Conference - November 27th, 2024
- 89bio to Participate in the 7th Annual Evercore HealthCONx Conference - November 27th, 2024
- Portage Biotech Reports Results for Fiscal Quarter Ended September 30, 2024 - November 27th, 2024
- Fulcrum Therapeutics to Participate in Upcoming December Conferences - November 27th, 2024
- Orchestra BioMed to Participate in the Piper Sandler 36th Annual Healthcare Conference - November 27th, 2024
- PROCEPT BioRobotics to Present at Upcoming 36th Annual Piper Sandler Healthcare Conference on December 4, 2024 - November 27th, 2024
- Lifecore Biomedical Amends and Extends Revolving Credit Facility with BMO - November 27th, 2024
- Fortrea to Present at the Citi Global Healthcare Conference - November 27th, 2024
- NKGen Biotech Receives Notifications From Nasdaq Related to Delayed Quarterly Report and Decision of the Nasdaq Hearings Panel - November 27th, 2024
- Fortrea to Present at the Evercore HealthCONx Conference - November 27th, 2024
- ANI Pharmaceuticals to Present at 36th Annual Piper Sandler Healthcare Conference - November 27th, 2024
- Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference - November 27th, 2024
- Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference - November 27th, 2024
- Idorsia enters into exclusive negotiations for global rights to aprocitentan - November 27th, 2024
- Novartis Kisqali® receives European Commission approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of... - November 27th, 2024
- 142,701 Orion Corporation A shares converted into B shares - November 27th, 2024
- Memo Therapeutics AG Announces Last Patient Enrolled in Phase II Clinical Trial of Potravitug for Treatment of BK Viremia in Kidney Transplant... - November 3rd, 2024
- Chimerix to Report Third Quarter 2024 Financial Results and Provide an Operational Update on November 7, 2024 - November 3rd, 2024
- Skye Bioscience to Announce Third Quarter 2024 Results - November 3rd, 2024
- Black Diamond Therapeutics to Participate in Upcoming Investor Conferences - November 3rd, 2024
- Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 3rd, 2024
- Praxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024 - November 3rd, 2024
- TG Therapeutics to Host Conference Call on Third Quarter 2024 Financial Results and Business Update - November 3rd, 2024
- Novo Nordisk A/S: Semaglutide 2.4 mg demonstrates superior improvement in both liver fibrosis and MASH resolution in the ESSENCE trial - November 3rd, 2024
- Galecto Reports Third Quarter 2024 Financial Results - November 3rd, 2024
- Shares Expected to Begin Trading on Split-Adjusted Basis on November 5, 2024 - November 3rd, 2024
- Zealand Pharma conference call on November 7 at 2pm CET (8am ET) to present third quarter 2024 financial results - November 3rd, 2024
- Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data - November 3rd, 2024
- Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and... - November 3rd, 2024
- Universe Pharmaceuticals INC Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency - November 3rd, 2024
- Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on... - November 3rd, 2024
- Disc Medicine to Host Conference Call on End of Phase 2 FDA Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP) - November 3rd, 2024
- Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split - November 3rd, 2024
- Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes - November 3rd, 2024
- NurExone Biologic Closes Final Tranche of Non-Brokered Private Placement and Provides Corporate Update - November 3rd, 2024
- ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer... - November 3rd, 2024
- Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting - October 6th, 2024
Tags: